Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders (Journal of Neurology (2006) 253, (SUPPL. 5) (39-49) DOI: 10.1007/s00415-006-5006-y);Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders

Journal of Neurology

Volumn 253, Issue SUPPL. 5, 2006, Pages 308-

  Steinbrecher, Andreas ^a   Berlit, Peter ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ALFRIED KRUPP KRANKENHAUS   (Germany)

Author keywords

Intravenous immunoglobulin; Lupus erythematosus; Rheumatic diseases; Vasculitis

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; HEMOLYTIC ANEMIA; HUMAN; MEDICAL LITERATURE; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; VASCULITIS;

EID: 33748955142     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0881-z     Document Type: Erratum

References (111)

1. Center for Disease Control and Prevention (CDC) (1999) Renal insufficiency and failure associated with immune globulin intravenous therapy. MMWR 48:518-521
2. Altmeyer P, Seifarth D, Bacharach-Buhles M (1999) High dosage intravenous immunoglobulin (IVIG) therapy in therapy-refractory ANCA-negative, necrotizing vasculitis. Hautarzt 50:853-858
3. Amital H, Levy Y, Shoenfeld Y (2000) Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 18:404-406
4. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75-83
5. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, Ingelmo M (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77: 195-207
6. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M (2001) Catastrophic antiphospho-lipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355-377
7. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ (1987) Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 82:624-629
8. Beales IL (1998) Gastrointestinal involvement in Behcet's syndrome. Am J Gastroenterol 93:2633
9. Berlit P, Steinbrecher A (2002) Cerebral vasculitis. Fortschr Neurol Psychiatr 70:663-677
10. Blum M, Andrassy K, Adler D, Hartmann M, Volcker HE (1997) Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 235:599-602
11. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM (1999) Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569-570
12. Boman S, Ballen JL, Seggev JS (1995) Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 238:375-377
13. Boom BW, Brand A, Bavinck JN, Eernisse JG, Daha MR, Vermeer BJ (1988) Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously. Arch Dermatol 124:1550-1553
14. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, Esplin MS, Spinnato J, Harger J (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182:122-127
15. Braun-Moscovici Y, Furst DE (2003) Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol 15:237-245
16. Canhao H, Fonseca JE, Rosa A (2000) Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren's syndrome. J Rheumatol 27:1102-1103
17. Cohen MG, Li EK (1991) Limited effects of intravenous IgG in treating systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 34:787-788
18. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM (1992) Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 120:926-928
19. Dupond JL, Gil H, de Wazieres B (1999) Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren's syndrome. Am J Med 106:125
20. Durez P, Tourne L, Feremans W, Mascart-Lemone F, Heenen M, Appelboom T (1998) Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren's syndrome. J Rheumatol 25:1032-1033
21. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96:1057-1061
22. Erkan D, Cervera R, Asheron R (2003) Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 48:3320-3327
23. Finkel TH, Torok TJ, Ferguson PJ, Durigon EL, Zaki SR, Leung DY, Harbeck, Gelfand EW, Saulsbury FT, Hollister JR et al. (1994) Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255-1258
24. Fong NC, Hui YW, Li CK, Chiu MC (2004) Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 25:31-34
25. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R (1994) Long-term i. v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 12:163-168
26. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T et al. (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2:1055-1058
27. Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46-50
28. Harber MA, Tso A, Taheri S, Tuck SM, Burns A (1999) Wegener's granulomatosis in pregnancy-the therapeutic dilemma. Nephrol Dial Transplant 14:1789-1791
29. Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673-675
30. Hebbar M, Hebbar-Savean K, Hachulla E, Brouillard M, Hatron PY, Devulder B (1995) Participation of cryoglobulinaemia in the severe peripheral neuropathies of primary Sjogren's syndrome. Ann Med Interne (Paris) 146:235-238
31. Heuss D, Schlotter-Weigel B, Sommer C (2003) Diagnosis and therapy of vasculitic neuropathy, Consensus statement of the German Centers for Neuromuscular Disease. Fortschr Neurol Psychiatr 71:172-186
32. Howse M, Bindoff L, Carmichael A (1998) Facial vasculitic rash associated with intravenous immunoglobulin. BMJ 317:1291
33. Hundt M, Manger K, Dorner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301-1302
34. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 93:433-439
35. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137-1139
36. Jayne DR, Lockwood CM (1993) Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336:469-472
37. Jayne DR, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150-1153
38. Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:619-630
39. Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:605-618
40. Jordan SC (1989) Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 53:S164-S169
41. Kanik KS, Yarboro CH, Naparstek Y, Plotz PH, Wilder RL (1996) Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum 39:1027-1029
42. th Edition. New York, McGraw-Hill, p 2607
43. Knezevic-Maramica I, Kruskall MS (2003) Intravenous immune globulins: an update for clinicians. Transfusion 43:1460-1480
44. Kreuter A, Gambichler T, Breuckmann F, Bechara FG, Rotterdam S, Stucker M, Altmeyer P (2004) Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 51:574-579
45. Kroiss M, Hohenleutner U, Gruss C, Glaessl A, Landthaler M, Stolz W (2001) Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa. Dermatology 203:188-189
46. Levy J (2001) New aspects in the management of ANCA-positive vasculitis. Nephrol Dial Transplant 16:1314-1317
47. Levy JB, Pusey CD (2000) Nephrotoxicity of intravenous immunoglobulin. Qjm 93:751-755
48. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 8:705-712
49. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, Fabbrizzi F, Terryberry J, Peter J, Shoenfeld Y (1999) Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119:231-238
50. Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321-327
51. Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y (2003) Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 62:1221-1223
52. Lewis M, Gibson T (2003) Systemic lupus erythematous with recurrent Guillain-Barre-like syndrome treated with intravenous immunoglobulins. Lupus 12:857-859
53. Lin CY, Hsu HC, Chiang H (1989) Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53:303-310
54. Machet L, Vincent O, Machet MC, Barruet K, Vaillant L, Lorette G (1995) Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents, Efficacy of treatment with intravenous immunoglobulins. Ann Dermatol Venereol 122:769-772
55. Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, Woodl ee PM (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33:1233-1239
56. Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS (1996) High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol 14:657-660
57. Masterson R, Pellicano R, Bleasel K, McMahon LP (2004) Wegener's granulomatosis in pregnancy: a novel approach to management. Am J Kidney Dis 44:e68-e72
58. rd, Brandt L (1982) Manifestations of Kawasaki disease in New England outbreak of 1980. J Pediatr 100:558-562
59. Mochizuki H, Kamakura K, Masaki T, Hirata A, Nakamura R, Motoyoshi K (2002) Motor dominant neuropathy in Sjogren's syndrome: report of two cases. Intern Med 41:142-146
60. Molina JA, Benito-Leon J, Bermejo F, Jimenez-Jimenez FJ, Olivan J (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 60:699
61. Monova D, Belovezhdov N, Altunkova I, Monov S (2002) Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 90:262-266
62. Muscat C, Bertotto A, Ercolani R, Bistoni O, Agea E, Cesarotti M, Fiorucci G, Spinozzi F, Gerli R (1995) Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 54:382-385
63. Muso E, Ito-Ihara T, Ono T, Imai E, Yamagata K, Akamatsu A, Suzuki K (2004) Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17-S18
64. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T (2004) Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 144:496-499
65. Nakagawa M, Watanabe N, Okuno M, Kondo M, Okagawa H, Taga T (2000) Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol 63:160-161
66. Nakamura S, Yoshida T, Ohtake S, Matsuda T (1986) Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol 76:115-118
67. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al. (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341-347
68. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708-1733
69. Odum J, D'Costa D, Freeth M, Taylor D, Smith N, MacWhannell A (2001) Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment. Nephrol Dial Transplant 16:403-406
70. Ong CS, Benson EM (2000) Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 143:447-449
71. Pagnoux C, Guillevin L (2005) Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol 17:41-48
72. Panzarino V, Estrada J, Benson K, Postoway N, Garratty G (1993) Autoimmune hemolytic anemia after Kawasaki disease in a child. Int J Hematol 57:259-263
73. Pascual J, Cid C, Berciano J (1998) High-dose i. v. immunoglobulin for peripheral neuropathy associated with Sjogren's syndrome. Neurology 51:650-651
74. Perez C, Guarch R, Rodrigo M, Gallego M, Ormazabal O (2002) Successful treatment of leucocytoclastic vasculitis and pancytopenia secondary to systemic lupus erythematosus with intravenous immunoglobulin. Br J Dermatol 147:180-182
75. Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M, Semprini AE (1997) Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 12:2388-2392
76. Ravat FE, Evans AV, Russell-Jones R (2002) Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol 147:166-169
77. Rewald E, Jaksic JC (1990) Behcet's syndrome treated with high-dose intravenous IgG and low-dose aspirin. J R Soc Med 83:652-653
78. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2-7
79. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S, Bonin P, Bierling P, Remy P, Lagrue G, Lang P, Weil B (1994) High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 120:476-484
80. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S et al. (1995) Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 69:327-334
81. Sanna G, Bertolaccini ML, Mathieu A (2003) Central nervous system lupus: a clinical approach to therapy. Lupus 12:935-942
82. Sawaji Y, Haneda N, Yamaguchi S, Kajino Y, Kishida K, Seto S, Konishi N, Waki K, Baba K, Arisawa K, Kamiya T, Mori C (1998) Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn 40:218-225
83. Schanz S, Ulmer A, Fierlbeck G (2003) Intravenous immunoglobulin in livedo vasculitis: a new treatment option? J Am Acad Dermatol 49:555-556
84. Schmidley JW (2000) Central nervous system angiitis. Boston, Butterworth-Heinemann
85. Schroeder JO, Zeuner RA, Euler HH, Loffler H (1996) High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 23:71-75
86. Seider N, Beiran I, Scharf J, Miller B (2001) Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 85:1287-1288
87. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y (1999) Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 18:170-173
88. th Edition. New York, McGraw-Hill, pp 2002-2014
89. Tabarki B, Mahdhaoui A, Selmi H, Yacoub M, Essoussi AS (2001) Kawasaki disease with predominant central nervous system involvement. Pediatr Neurol 25:239-241
90. Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I (2003) Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. IV immunoglobulin. Neurology 60:503-505
91. Taylor CT, Buring SM, Taylor KH (1999) Treatment of Wegener's granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 33:1055-1059
92. Terai M, Shulman ST (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131:888-893
93. Terasawa K, Ichinose E, Matsuishi T, Kato H (1983) Neurological complications in Kawasaki disease. Brain Dev 5:371-374
94. Tomer Y, Shoenfeld Y (1992) Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 10:391-393
95. Toth C, Trotter M, Clark A, Zochodne D (2003) Mononeuropathy multiplex in association with livedoid vasculitis. Muscle Nerve 28:634-639
96. Toubi E, Kessel A, Shoenfeld Y (2005) High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395-402
97. Tran MD, Becherel PA, Cordel N, Piette JC, Frances C (2001) "Idiopathic" white atrophy. Ann Dermatol Venereol 128: 1003-1007
98. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G (2003) Randomized Study of Subcutaneous Low Molecular Weight Heparin Plus Aspirin Versus Intravenous Immunoglobulin in the Treatment of Recurrent Fetal Loss Associated With Antiphospholipid Antibodies. Arthritis Rheum 48:728-731
99. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K (2004) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80-87
100. Tumiati B, Casoli P, Veneziani M, Rinaldi G (1992) High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 35:1126-1133
101. Tuso P, Moudgil A, Hay J, Goodman D, Kamil E, Koyyana R, Jordan SC (1992) Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 20:504-508
102. Ulinski T, Martin H, Mac Gregor B, Dardelin R, Cochat P (2005) Fatal neurologic involvement in pediatric Wegener's granulomatosis. Pediatr Neurol 32:278-281
103. Uziel Y, Silverman ED (1998) Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol 16:187-189
104. Viguier M, Guillevin L, Laroche L (2001) Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 344:1481-1482
105. Vogele C, Andrassy K, Schmidbauer JM, Krastel H, Adler D, Ritz E (1994) Retinal vasculitis and uveitis-an adverse reaction to intravenous immunoglobulins? Nephron 67:363
106. Wetter DA, Davis MD, Yiannias JA, Gibson LE, Dahl MV, el-Azhary RA, Bruce AJ, Lookingbill DP, Ahmed I, Schroeter AL, Pittelkow MR (2005) Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 80:41-47
107. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y (1993) Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 20:495-498
108. Winkelmann RK, Schroeter AL, Kierland RR, Ryan TM (1974) Clinical studies of livedoid vasculitis: (segmental hyalinizing vasculitis). Mayo Clin Proc 49:746-750
109. Wooten MD, Jasin HE (1996) Mixed cryoglobulinemia and vasculitis: a novel pathogenic mechanism. J Rheumatol 23:1278-1281
110. Yasue T (1986) Livedoid vasculitis and central nervous system involvement in systemic lupus erythematosus. Arch Dermatol 122:66-70
111. Yebra M, Barrios Y, Rincon J, Sanjuan I, Diaz-Espada F (2002) Severe cutaneous vasculitis following intravenous infusion of gammaglobulin in a patient with type II mixed cryoglobulinemia. Clin Exp Rheumatol 20:225-227